Ryan A. McTaggart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan A. McTaggart has a total of 348 co-authors. Here are the top co-authors by number of shared publications:
- Mayank Goyal
University of Calgary
13 shared publications - Andrew Michael Demchuk
Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada (A.M.D.).
11 shared publications - Johanna Maria Ospel
University of Calgary
10 shared publications - Michael Douglas Hill
University of Calgary
10 shared publications - Raul Gomes Nogueira
Department of Neurology and Neurosurgery, UPMC Stroke Institute, University of Pittsburgh School of Medicine, PA
10 shared publications - Alexandre Yves Poppe
Department of Neurology, CHUM-Centre hospitalier de l’Université de Montréal, QC, Canada (A.Y.P.).
9 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (6)
Site Versus Core Lab-Adjudicated First- and Final-Pass eTICI Scores Compared During Off and Normal Hours: Insights From the ASSIST Registry
BACKGROUND: Data from the ASSIST registry were analyzed to assess whether site-reported expanded Treatment in Cerebral Infarction (eTICI) scores differ from those reported by the core lab during off hours compared with normal hours. We also assessed whether outcomes are worse in procedures performed during off hours. METHODS: Details from the registry have been previously published. Regression models were performed for first-pass treatment of target occlusion resulting in ≥2c by the core lab, agreement for final pass ≥2c, modified Rankin Scale 0 to 2 at 90 days, and whether first-pass eTICI ≥2c agreed between the core lab and site-reported assessments. RESULTS: A total of 1318 patients were included. Overall, agreement between core-lab and site-reported eTICI for first-pass eTICI ≥2c occurred in 86.7% and 78.5% for final eTICI ≥2c. Agreement for first-pass and final-pass eTICI ≥2c occurred in 87.2% and 77.7% during normal hours and 86.1% and 79.3% during off hours. Good functional outcomes occurred in 55.5% of patients presenting during normal hours and 53.8% of patients presenting during off hours. Off-hour versus normal-hour procedures were not significantly associated with first-pass efficacy, modified Rankin Scale 0 to 2 at 90 days, or whether first-pass eTICI agreed between the core lab and site-reported assessments in adjusted regression analyses. CONCLUSIONS: There was a higher level of agreement between core-lab and site-reported first-pass eTICI scores during all hours, while agreement occurred less often for final reperfusion. These results suggest a high level of correlation regardless of the time of the procedure between site-adjudicated and core-lab-adjudicated successful reperfusion grading. There were no significant differences in outcomes irrespective of the timing of thrombectomy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (6)
Open AccessSite Versus Core Lab-Adjudicated First- and Final-Pass eTICI Scores Compared During Off and Normal Hours: Insights From the ASSIST Registry
BACKGROUND: Data from the ASSIST registry were analyzed to assess whether site-reported expanded Treatment in Cerebral Infarction (eTICI) scores differ from those reported by the core lab during off hours compared with normal hours. We also assessed whether outcomes are worse in procedures performed during off hours. METHODS: Details from the registry have been previously published. Regression models were performed for first-pass treatment of target occlusion resulting in ≥2c by the core lab, agreement for final pass ≥2c, modified Rankin Scale 0 to 2 at 90 days, and whether first-pass eTICI ≥2c agreed between the core lab and site-reported assessments. RESULTS: A total of 1318 patients were included. Overall, agreement between core-lab and site-reported eTICI for first-pass eTICI ≥2c occurred in 86.7% and 78.5% for final eTICI ≥2c. Agreement for first-pass and final-pass eTICI ≥2c occurred in 87.2% and 77.7% during normal hours and 86.1% and 79.3% during off hours. Good functional outcomes occurred in 55.5% of patients presenting during normal hours and 53.8% of patients presenting during off hours. Off-hour versus normal-hour procedures were not significantly associated with first-pass efficacy, modified Rankin Scale 0 to 2 at 90 days, or whether first-pass eTICI agreed between the core lab and site-reported assessments in adjusted regression analyses. CONCLUSIONS: There was a higher level of agreement between core-lab and site-reported first-pass eTICI scores during all hours, while agreement occurred less often for final reperfusion. These results suggest a high level of correlation regardless of the time of the procedure between site-adjudicated and core-lab-adjudicated successful reperfusion grading. There were no significant differences in outcomes irrespective of the timing of thrombectomy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (6)
Clinical Improvement, No Improvement, and Worsening at 24 Hours Following Reperfusion in Patients With Stroke due to Large-Vessel Occlusion
BACKGROUND: Restoring blood flow to ischemic tissue is the cornerstone of acute stroke therapy and is usually beneficial. However, when reperfusion is achieved for severely injured tissue, it is often futile and may occasionally cause harm. We aim to determine the prevalence and variables associated with clinical no improvement or acute worsening at 24 hours despite reperfusion in patients with large-vessel occlusion stroke treated with endovascular thrombectomy. METHODS: Data are from ESCAPE-NA1 (Safety and Efficacy of Nerinetide [NA-1] in Subjects Undergoing Endovascular Thrombectomy for Stroke), a randomized trial of nerinetide in patients with acute large-vessel occlusion stroke undergoing endovascular thrombectomy. Patients with unsuccessful recanalization (expanded Thrombolysis in Cerebral Infarction <2b), infarcts in new vascular territories, vessel perforation, or remote parenchymal hemorrhage were excluded. Clinical outcomes after reperfusion were classified by 24-hour National Institutes of Health Stroke Scale changes compared with baseline: improvement (≥4-point improvement), no improvement (±3-point from baseline), and worsening (≥4-point worsening). Baseline variables associated with worsening were identified using logistic regression. In the computed tomography perfusion subgroup, prevalence of parenchymal hemorrhage (any parenchymal hematoma) and infarct progression (final infarct volume exceeding the initial hypoperfused region) were evaluated. RESULTS: A total of 833 patients were included (median age, 70.9 years [interquartile range, 60.7–79.4]; 51.4% men). After reperfusion, 669 (80.3%) patients improved, 135 (16.2%) showed no improvement, and 29 (3.5%) worsened. Independent predictors of worsening were longer onset-to-reperfusion time (adjusted odds ratio, 1.02 [95% CI, 1.00–1.04] per 10-minute increase) and greater degree of sedation (adjusted odds ratio, 1.78 [95% CI, 1.29–2.46] per category of none, conscious sedation, and general anesthesia). In the computed tomography perfusion subgroup (n=414), among patients with worsening after reperfusion, parenchymal hemorrhage was seen in 5 patients (31.3%) and infarct progression in 4 patients (25%). CONCLUSIONS: Clinical worsening in the acute period (ie, early neurological deterioration) despite reperfusion and the absence of procedure-related complications was rare in this selected large-vessel occlusion stroke cohort (3.5%). Factors associated with worsening after reperfusion were a longer time from symptom onset-to-reperfusion and a higher degree of sedation.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (6)
Open AccessClinical Improvement, No Improvement, and Worsening at 24 Hours Following Reperfusion in Patients With Stroke due to Large-Vessel Occlusion
BACKGROUND: Restoring blood flow to ischemic tissue is the cornerstone of acute stroke therapy and is usually beneficial. However, when reperfusion is achieved for severely injured tissue, it is often futile and may occasionally cause harm. We aim to determine the prevalence and variables associated with clinical no improvement or acute worsening at 24 hours despite reperfusion in patients with large-vessel occlusion stroke treated with endovascular thrombectomy. METHODS: Data are from ESCAPE-NA1 (Safety and Efficacy of Nerinetide [NA-1] in Subjects Undergoing Endovascular Thrombectomy for Stroke), a randomized trial of nerinetide in patients with acute large-vessel occlusion stroke undergoing endovascular thrombectomy. Patients with unsuccessful recanalization (expanded Thrombolysis in Cerebral Infarction <2b), infarcts in new vascular territories, vessel perforation, or remote parenchymal hemorrhage were excluded. Clinical outcomes after reperfusion were classified by 24-hour National Institutes of Health Stroke Scale changes compared with baseline: improvement (≥4-point improvement), no improvement (±3-point from baseline), and worsening (≥4-point worsening). Baseline variables associated with worsening were identified using logistic regression. In the computed tomography perfusion subgroup, prevalence of parenchymal hemorrhage (any parenchymal hematoma) and infarct progression (final infarct volume exceeding the initial hypoperfused region) were evaluated. RESULTS: A total of 833 patients were included (median age, 70.9 years [interquartile range, 60.7–79.4]; 51.4% men). After reperfusion, 669 (80.3%) patients improved, 135 (16.2%) showed no improvement, and 29 (3.5%) worsened. Independent predictors of worsening were longer onset-to-reperfusion time (adjusted odds ratio, 1.02 [95% CI, 1.00–1.04] per 10-minute increase) and greater degree of sedation (adjusted odds ratio, 1.78 [95% CI, 1.29–2.46] per category of none, conscious sedation, and general anesthesia). In the computed tomography perfusion subgroup (n=414), among patients with worsening after reperfusion, parenchymal hemorrhage was seen in 5 patients (31.3%) and infarct progression in 4 patients (25%). CONCLUSIONS: Clinical worsening in the acute period (ie, early neurological deterioration) despite reperfusion and the absence of procedure-related complications was rare in this selected large-vessel occlusion stroke cohort (3.5%). Factors associated with worsening after reperfusion were a longer time from symptom onset-to-reperfusion and a higher degree of sedation.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (5)
Clinical and Demographic Factors Associated With Hemorrhagic Transformation Subtypes After Endovascular Thrombectomy for Acute Ischemic Stroke
BACKGROUND: Hemorrhagic transformation (HT) after endovascular thrombectomy (EVT) is associated with worse neurological outcomes. We sought to identify clinical and demographic factors associated with HT and HT subtypes after EVT. METHODS: Patients with anterior circulation large vessel occlusion who underwent first-pass EVT using different thrombectomy devices were enrolled in a global multicenter prospective registry. Baseline clinical characteristics were compared between individuals with and without HT and across HT subtypes 24 hours after EVT. Multivariable logistic regression models were used to determine risk factors associated with HT and HT subtypes. RESULTS: The study cohort comprised 1453 patients. Imaging evidence of HT occurred in 40% of patients, of whom 3.2% had symptomatic HT. In a multivariable regression analysis, diabetes (odds ratio [OR], 1.47 [95% CI, 1.09–1.99]; P =0.01), National Institutes of Health Stroke Scale score of 16 to 19 (OR, 1.45 [95% CI, 1.09–1.94]; P =0.01), National Institutes of Health Stroke Scale score ≥20 (OR, 1.98 [95% CI, 1.56–2.50]; P P P =0.0003) were independent risk factors for HT. Atrial fibrillation (OR, 0.75 [95% CI, 0.58–0.96]; P =0.02) was a protective factor against HT. Baseline Alberta Stroke Program Early Computed Tomography Score <8, elevated baseline serum glucose, and higher baseline National Institutes of Health Stroke Scale scores were independent predictors of hemorrhagic infarction-1 and hemorrhagic infarction-2. Diabetes was significantly associated with hemorrhagic infarction-2, and Alberta Stroke Program Early Computed Tomography Score <8 was significantly associated with subarachnoid hemorrhage. CONCLUSIONS: Given that certain risk factors are associated with specific subtypes of HT, our analysis demonstrates the importance of not only reporting symptomatic HT but also classifying HT into subtypes in clinical trials. Identifying risk factors associated with HT subtypes may improve prognostic accuracy and guide post-EVT monitoring. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (5)
Open AccessClinical and Demographic Factors Associated With Hemorrhagic Transformation Subtypes After Endovascular Thrombectomy for Acute Ischemic Stroke
BACKGROUND: Hemorrhagic transformation (HT) after endovascular thrombectomy (EVT) is associated with worse neurological outcomes. We sought to identify clinical and demographic factors associated with HT and HT subtypes after EVT. METHODS: Patients with anterior circulation large vessel occlusion who underwent first-pass EVT using different thrombectomy devices were enrolled in a global multicenter prospective registry. Baseline clinical characteristics were compared between individuals with and without HT and across HT subtypes 24 hours after EVT. Multivariable logistic regression models were used to determine risk factors associated with HT and HT subtypes. RESULTS: The study cohort comprised 1453 patients. Imaging evidence of HT occurred in 40% of patients, of whom 3.2% had symptomatic HT. In a multivariable regression analysis, diabetes (odds ratio [OR], 1.47 [95% CI, 1.09–1.99]; P =0.01), National Institutes of Health Stroke Scale score of 16 to 19 (OR, 1.45 [95% CI, 1.09–1.94]; P =0.01), National Institutes of Health Stroke Scale score ≥20 (OR, 1.98 [95% CI, 1.56–2.50]; P P P =0.0003) were independent risk factors for HT. Atrial fibrillation (OR, 0.75 [95% CI, 0.58–0.96]; P =0.02) was a protective factor against HT. Baseline Alberta Stroke Program Early Computed Tomography Score <8, elevated baseline serum glucose, and higher baseline National Institutes of Health Stroke Scale scores were independent predictors of hemorrhagic infarction-1 and hemorrhagic infarction-2. Diabetes was significantly associated with hemorrhagic infarction-2, and Alberta Stroke Program Early Computed Tomography Score <8 was significantly associated with subarachnoid hemorrhage. CONCLUSIONS: Given that certain risk factors are associated with specific subtypes of HT, our analysis demonstrates the importance of not only reporting symptomatic HT but also classifying HT into subtypes in clinical trials. Identifying risk factors associated with HT subtypes may improve prognostic accuracy and guide post-EVT monitoring. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well
BACKGROUND: Adjunct therapies are needed for patients with acute ischemic stroke who fare poorly, despite standard-of-care endovascular thrombectomy (EVT). RESCUE (A Randomized, Blinded, Placebo-Controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) tested the cytoprotective experimental drug RNS60 in patients with acute ischemic stroke, adjunct to EVT with or without prior standard-of-care thrombolytic treatment. METHODS: RESCUE, a randomized, placebo-controlled, double-blind, phase 2 study, enrolled 83 participants eligible for EVT within 24 hours since last known well, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour. A post hoc analysis evaluated safety and efficacy in a subpopulation of 62 participants enrolled within 12 hours since last known well. Efficacy end points included modified Rankin Scale score, post-EVT infarct growth, National Institutes of Health Stroke Scale score, Barthel Index score, EuroQoL, and duration of hospitalization and discharge disposition. RESULTS: In this subpopulation, RNS60 1.0 mL/kg per hour was generally safe and well tolerated and reduced post-EVT infarct growth compared with placebo (least squares mean difference, 22.2; P =0.05). Of the participants treated with RNS60 1.0 mL/kg per hour, 72.2% achieved a 90-day modified Rankin Scale score of 0 to 2, and 72.2% achieved a Barthel Index score ≥95, compared with 36.8% (for both measures) of those receiving placebo, although the differences were not statistically significant ( P =0.09 for both modified Rankin Scale and Barthel Index scores). Consistent but smaller differences to placebo were seen in the RNS60 0.5 mL/kg per hour group, which suggests a dose-dependent effect of RNS60. Participants in the RNS60 1.0 mL/kg per hour group were also released earlier from the hospital than those in the placebo group (mean [SD]: 6.0 [5.10] days versus 10.8 [6.84] days; mean difference [SE], −4.8 [1.99]; P =0.02). Final infarct volumes at 48 hours post-EVT correlated with modified Rankin Scale scores at day 90 for RNS60 1.0 mL/kg per (Pearson r =0.65; P =0.005) and placebo ( r =0.65; P =0.007). CONCLUSIONS: Effects of RNS60 were favorable compared with placebo in the analyzed subpopulation, warranting further investigation in this population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Open AccessRNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well
BACKGROUND: Adjunct therapies are needed for patients with acute ischemic stroke who fare poorly, despite standard-of-care endovascular thrombectomy (EVT). RESCUE (A Randomized, Blinded, Placebo-Controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) tested the cytoprotective experimental drug RNS60 in patients with acute ischemic stroke, adjunct to EVT with or without prior standard-of-care thrombolytic treatment. METHODS: RESCUE, a randomized, placebo-controlled, double-blind, phase 2 study, enrolled 83 participants eligible for EVT within 24 hours since last known well, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour. A post hoc analysis evaluated safety and efficacy in a subpopulation of 62 participants enrolled within 12 hours since last known well. Efficacy end points included modified Rankin Scale score, post-EVT infarct growth, National Institutes of Health Stroke Scale score, Barthel Index score, EuroQoL, and duration of hospitalization and discharge disposition. RESULTS: In this subpopulation, RNS60 1.0 mL/kg per hour was generally safe and well tolerated and reduced post-EVT infarct growth compared with placebo (least squares mean difference, 22.2; P =0.05). Of the participants treated with RNS60 1.0 mL/kg per hour, 72.2% achieved a 90-day modified Rankin Scale score of 0 to 2, and 72.2% achieved a Barthel Index score ≥95, compared with 36.8% (for both measures) of those receiving placebo, although the differences were not statistically significant ( P =0.09 for both modified Rankin Scale and Barthel Index scores). Consistent but smaller differences to placebo were seen in the RNS60 0.5 mL/kg per hour group, which suggests a dose-dependent effect of RNS60. Participants in the RNS60 1.0 mL/kg per hour group were also released earlier from the hospital than those in the placebo group (mean [SD]: 6.0 [5.10] days versus 10.8 [6.84] days; mean difference [SE], −4.8 [1.99]; P =0.02). Final infarct volumes at 48 hours post-EVT correlated with modified Rankin Scale scores at day 90 for RNS60 1.0 mL/kg per (Pearson r =0.65; P =0.005) and placebo ( r =0.65; P =0.007). CONCLUSIONS: Effects of RNS60 were favorable compared with placebo in the analyzed subpopulation, warranting further investigation in this population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Clinical and Angiographic Outcomes in Patients With Tandem Occlusion Thrombectomy: Analysis From the ASSIST International Registry
BACKGROUND: Tandem lesions (TLs) are a subtype of acute ischemic stroke, which involve an extracranial carotid lesion (ie, severe carotid stenosis ≥70%) with large vessel occlusion. While large vessel occlusion has a standard approach with mechanical thrombectomy (MT), the best practice for intervention of the carotid lesion is not well-established. Utilizing data from the ASSIST registry, we investigated the differences in clinical and procedural outcomes between acute versus nonacute stenting. METHODS: The ASSIST registry (an international acute ischemic stroke MT prospective study) was utilized to identify the subgroup of patients with acute ischemic stroke secondary to TL who received MT. The TLs were grouped by MT+acute carotid stenting (CAS) versus MT+acute carotid nonstenting. The demographics and clinical outcomes (90-day modified Rankin Scale score) were compared between TL and non-TL groups, and between MT+CAS and MT+acute carotid nonstenting. Multivariable analyses were performed to determine independent predictors of clinical outcomes. RESULTS: A total of 183 of 1270 (14.4%) TLs were identified in the ASSIST registry. MT+CAS was performed in 83 of 183 (45.4%) subjects, and 100 of 183 (54.6%) received MT+acute carotid nonstenting. There are no significant differences at baseline between the 2 groups in the National Institutes of Health Stroke Scale score, Alberta Stroke Program Early Computed Tomography Score, or target vessel. Achieving a modified Rankin Scale score of 0 to 2 at 90 days was 70.9% in the MT+CAS group versus 48.9% in the MT+acute carotid nonstenting group ( P =0.001), with a modified Rankin Scale score of 0 to 2 being significantly associated with the MT+CAS group in multivariable analysis (odds ratio, 2.14 [95% CI, 1.01–4.51]). There was no significant difference in mortality or symptomatic intracerebral hemorrhage between the groups. CONCLUSIONS: In acute ischemic stroke, secondary to TLs treatment with thrombectomy and acute carotid stenting is associated with improved 90-day functional outcome without an increase in symptomatic intracerebral hemorrhage compared with no acute stenting approach. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Open AccessClinical and Angiographic Outcomes in Patients With Tandem Occlusion Thrombectomy: Analysis From the ASSIST International Registry
BACKGROUND: Tandem lesions (TLs) are a subtype of acute ischemic stroke, which involve an extracranial carotid lesion (ie, severe carotid stenosis ≥70%) with large vessel occlusion. While large vessel occlusion has a standard approach with mechanical thrombectomy (MT), the best practice for intervention of the carotid lesion is not well-established. Utilizing data from the ASSIST registry, we investigated the differences in clinical and procedural outcomes between acute versus nonacute stenting. METHODS: The ASSIST registry (an international acute ischemic stroke MT prospective study) was utilized to identify the subgroup of patients with acute ischemic stroke secondary to TL who received MT. The TLs were grouped by MT+acute carotid stenting (CAS) versus MT+acute carotid nonstenting. The demographics and clinical outcomes (90-day modified Rankin Scale score) were compared between TL and non-TL groups, and between MT+CAS and MT+acute carotid nonstenting. Multivariable analyses were performed to determine independent predictors of clinical outcomes. RESULTS: A total of 183 of 1270 (14.4%) TLs were identified in the ASSIST registry. MT+CAS was performed in 83 of 183 (45.4%) subjects, and 100 of 183 (54.6%) received MT+acute carotid nonstenting. There are no significant differences at baseline between the 2 groups in the National Institutes of Health Stroke Scale score, Alberta Stroke Program Early Computed Tomography Score, or target vessel. Achieving a modified Rankin Scale score of 0 to 2 at 90 days was 70.9% in the MT+CAS group versus 48.9% in the MT+acute carotid nonstenting group ( P =0.001), with a modified Rankin Scale score of 0 to 2 being significantly associated with the MT+CAS group in multivariable analysis (odds ratio, 2.14 [95% CI, 1.01–4.51]). There was no significant difference in mortality or symptomatic intracerebral hemorrhage between the groups. CONCLUSIONS: In acute ischemic stroke, secondary to TLs treatment with thrombectomy and acute carotid stenting is associated with improved 90-day functional outcome without an increase in symptomatic intracerebral hemorrhage compared with no acute stenting approach. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03845491.
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2386-2397
Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke
BACKGROUND: Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE (A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic. METHODS: This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale. RESULTS: The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3]; P <0.05). No statistically significant differences were observed in other efficacy end points, but a higher proportion of participants in the RNS60 1.0 mL/kg per hour group had reduced disability (modified Rankin Scale score of 0–2) and functional independence (Barthel Index ≥95) on Day 90. CONCLUSIONS: RNS60 was safe and well tolerated. The RNS60 1.0 mL/kg per hour reduced infarct growth after endovascular thrombectomy compared with placebo. This suggests a benefit warranting investigation in a larger, appropriately powered trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2386-2397
Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke
BACKGROUND: Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE (A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic. METHODS: This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale. RESULTS: The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3]; P <0.05). No statistically significant differences were observed in other efficacy end points, but a higher proportion of participants in the RNS60 1.0 mL/kg per hour group had reduced disability (modified Rankin Scale score of 0–2) and functional independence (Barthel Index ≥95) on Day 90. CONCLUSIONS: RNS60 was safe and well tolerated. The RNS60 1.0 mL/kg per hour reduced infarct growth after endovascular thrombectomy compared with placebo. This suggests a benefit warranting investigation in a larger, appropriately powered trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213619
Impact of Brain Frailty on Clinical Presentation and Neurologic Recovery in Acute Ischemic Stroke Patients Undergoing Thrombectomy
Brain frailty impairs the ability to compensate for brain dysfunction and is linked to worse outcomes after stroke. Stroke severity at presentation is a key determinant of outcomes in acute ischemic stroke. This study aimed to examine the impact of brain frailty on initial stroke severity and recovery in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT). We conducted a post hoc analysis of the ESCAPE-NA1 randomized-controlled trial that investigated the efficacy and safety of the neuroprotectant nerinetide in patients with AIS who received EVT. Brain frailty markers (cortical atrophy, subcortical atrophy, white matter hyperintensities, chronic infarcts) were visually assessed from baseline noncontrast CT scans. We explored the association between these markers and admission stroke severity (National Institutes of Health Stroke Scale [NIHSS] score) using multivariable quantile regression. We also assessed the NIHSS trajectory over 90 days using repeated-measures analysis. Models were adjusted for relevant covariates. Among 1,102 participants (mean age 69.5 years; 49.7% female), NIHSS scores at baseline were higher in patients with cortical atrophy and those with chronic infarcts compared with patients having no cortical atrophy or chronic infarcts after adjusting for confounders (adjusted difference for GCA1 vs GCA0 = 1.25 points [95% CI 0.18-2.31], p = 0.021; adjusted difference for presence of chronic infarcts = 1.27 points [95% CI 0.007-2.53, p = 0.049]). Subcortical atrophy, white matter hyperintensity burden, lacunes, and overall brain frailty were not associated with NIHSS scores at presentation. A repeated-measures analysis showed consistent higher NIHSS scores in individuals with brain frailty compared with those without, after the acute phase throughout the 90-day follow-up period (NIHSS score at 30 days, adjusted difference for total brain frailty score 1 vs 0 = 1.16 points [95% CI 0.35-1.96], p = 0.01; brain frailty score 2/3 vs 0 = 0.98 [95% CI 0.08-1.88], p = 0.03; NIHSS score at 90 days (adjusted difference for brain frailty score 1 vs 0 = 0.97 [95% CI 0.19-1.75], p = 0.01; brain frailty score 2/3 vs 0 = 0.85 [95% CI -0.01 to -1.71], p = 0.05). This study highlights the association of brain frailty with the clinical presentation and recovery trajectory of patients with AIS undergoing EVT. Specifically, cortical atrophy was independently associated with baseline stroke severity, and the total burden of brain frailty was independently associated with NIHSS recovery trajectories. The results emphasize the importance of considering brain frailty in acute stroke management and prognostication.
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213619
Impact of Brain Frailty on Clinical Presentation and Neurologic Recovery in Acute Ischemic Stroke Patients Undergoing Thrombectomy
Brain frailty impairs the ability to compensate for brain dysfunction and is linked to worse outcomes after stroke. Stroke severity at presentation is a key determinant of outcomes in acute ischemic stroke. This study aimed to examine the impact of brain frailty on initial stroke severity and recovery in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT). We conducted a post hoc analysis of the ESCAPE-NA1 randomized-controlled trial that investigated the efficacy and safety of the neuroprotectant nerinetide in patients with AIS who received EVT. Brain frailty markers (cortical atrophy, subcortical atrophy, white matter hyperintensities, chronic infarcts) were visually assessed from baseline noncontrast CT scans. We explored the association between these markers and admission stroke severity (National Institutes of Health Stroke Scale [NIHSS] score) using multivariable quantile regression. We also assessed the NIHSS trajectory over 90 days using repeated-measures analysis. Models were adjusted for relevant covariates. Among 1,102 participants (mean age 69.5 years; 49.7% female), NIHSS scores at baseline were higher in patients with cortical atrophy and those with chronic infarcts compared with patients having no cortical atrophy or chronic infarcts after adjusting for confounders (adjusted difference for GCA1 vs GCA0 = 1.25 points [95% CI 0.18-2.31], p = 0.021; adjusted difference for presence of chronic infarcts = 1.27 points [95% CI 0.007-2.53, p = 0.049]). Subcortical atrophy, white matter hyperintensity burden, lacunes, and overall brain frailty were not associated with NIHSS scores at presentation. A repeated-measures analysis showed consistent higher NIHSS scores in individuals with brain frailty compared with those without, after the acute phase throughout the 90-day follow-up period (NIHSS score at 30 days, adjusted difference for total brain frailty score 1 vs 0 = 1.16 points [95% CI 0.35-1.96], p = 0.01; brain frailty score 2/3 vs 0 = 0.98 [95% CI 0.08-1.88], p = 0.03; NIHSS score at 90 days (adjusted difference for brain frailty score 1 vs 0 = 0.97 [95% CI 0.19-1.75], p = 0.01; brain frailty score 2/3 vs 0 = 0.85 [95% CI -0.01 to -1.71], p = 0.05). This study highlights the association of brain frailty with the clinical presentation and recovery trajectory of patients with AIS undergoing EVT. Specifically, cortical atrophy was independently associated with baseline stroke severity, and the total burden of brain frailty was independently associated with NIHSS recovery trajectories. The results emphasize the importance of considering brain frailty in acute stroke management and prognostication.
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , 14-21
Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial
BACKGROUND: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume. METHODS: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model. RESULTS: Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline ( P interaction =0.02) and postdose ( P interaction =0.04) systolic blood pressure and use of general anesthesia ( P interaction =0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume ( P interaction =0.08). CONCLUSIONS: Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , 14-21
Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial
BACKGROUND: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume. METHODS: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model. RESULTS: Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline ( P interaction =0.02) and postdose ( P interaction =0.04) systolic blood pressure and use of general anesthesia ( P interaction =0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume ( P interaction =0.08). CONCLUSIONS: Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1349-1358
Influence of Infarct Morphology and Patterns on Cognitive Outcomes After Endovascular Thrombectomy
BACKGROUND: To assess the association of qualitative and quantitative infarct characteristics and 3 cognitive outcome tests, namely the Montreal Cognitive Assessment (MOCA) for mild cognitive impairment, the Boston Naming Test for visual confrontation naming, and the Sunnybrook Neglect Assessment Procedure for neglect, in large vessel occlusion stroke. METHODS: Secondary observational cohort study using data from the randomized-controlled ESCAPE-NA1 trial (Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke), in which patients with large vessel occlusion undergoing endovascular treatment were randomized to receive either intravenous Nerinetide or placebo. MOCA, Sunnybrook Neglect Assessment Procedure, and 15-item Boston Naming Test were obtained at 90 days. Total infarct volume, gray matter, and white matter infarct volumes were manually measured on 24-hour follow-up imaging. Infarcts were also visually classified as either involving the gray matter only or both the gray and white matter and scattered versus territorial. Associations of infarct variables and cognitive outcomes were analyzed using multivariable ordinal or binary logistic regression models. RESULTS: Of 1105 patients enrolled in ESCAPE-NA1, 1026 patients with visible infarcts on 24-hour follow-up imaging were included. MOCA and Sunnybrook Neglect Assessment Procedure were available for 706 (68.8%) patients and the 15-item Boston Naming Test was available for 682 (66.5%) patients. Total infarct volume was associated with worse MOCA scores (adjusted common odds ratio per 10 mL increase, 1.05 [95% CI, 1.04–1.06]). After adjusting for baseline variables and total infarct volume, mixed gray and white matter involvement (versus gray matter-only adjusted common odds ratio, 1.92 [95% CI, 1.37–2.69]), white matter infarct volume (adjusted common odds ratio per 10 mL increase 1.36 [95% CI, 1.18–1.58]) and territorial (versus scattered) infarct pattern (adjusted common odds ratio, 1.65 [95% CI, 1.15–2.38]) were associated with worse MOCA scores. Results for Sunnybrook Neglect Assessment Procedure and 15-item Boston Naming Test were similar, except for the territorial infarct pattern, which did not reach statistical significance in multivariable analysis. CONCLUSIONS: Besides total infarct volume, infarcts that involve the white matter and that show a territorial distribution were associated with worse cognitive outcomes, even after adjusting for total infarct volume.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1349-1358
Influence of Infarct Morphology and Patterns on Cognitive Outcomes After Endovascular Thrombectomy
BACKGROUND: To assess the association of qualitative and quantitative infarct characteristics and 3 cognitive outcome tests, namely the Montreal Cognitive Assessment (MOCA) for mild cognitive impairment, the Boston Naming Test for visual confrontation naming, and the Sunnybrook Neglect Assessment Procedure for neglect, in large vessel occlusion stroke. METHODS: Secondary observational cohort study using data from the randomized-controlled ESCAPE-NA1 trial (Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke), in which patients with large vessel occlusion undergoing endovascular treatment were randomized to receive either intravenous Nerinetide or placebo. MOCA, Sunnybrook Neglect Assessment Procedure, and 15-item Boston Naming Test were obtained at 90 days. Total infarct volume, gray matter, and white matter infarct volumes were manually measured on 24-hour follow-up imaging. Infarcts were also visually classified as either involving the gray matter only or both the gray and white matter and scattered versus territorial. Associations of infarct variables and cognitive outcomes were analyzed using multivariable ordinal or binary logistic regression models. RESULTS: Of 1105 patients enrolled in ESCAPE-NA1, 1026 patients with visible infarcts on 24-hour follow-up imaging were included. MOCA and Sunnybrook Neglect Assessment Procedure were available for 706 (68.8%) patients and the 15-item Boston Naming Test was available for 682 (66.5%) patients. Total infarct volume was associated with worse MOCA scores (adjusted common odds ratio per 10 mL increase, 1.05 [95% CI, 1.04–1.06]). After adjusting for baseline variables and total infarct volume, mixed gray and white matter involvement (versus gray matter-only adjusted common odds ratio, 1.92 [95% CI, 1.37–2.69]), white matter infarct volume (adjusted common odds ratio per 10 mL increase 1.36 [95% CI, 1.18–1.58]) and territorial (versus scattered) infarct pattern (adjusted common odds ratio, 1.65 [95% CI, 1.15–2.38]) were associated with worse MOCA scores. Results for Sunnybrook Neglect Assessment Procedure and 15-item Boston Naming Test were similar, except for the territorial infarct pattern, which did not reach statistical significance in multivariable analysis. CONCLUSIONS: Besides total infarct volume, infarcts that involve the white matter and that show a territorial distribution were associated with worse cognitive outcomes, even after adjusting for total infarct volume.
- 26 January 2024
- Published by Springer Nature in Neuroradiology
- Vol. 66 (4) , 621-629
Modeling diffusion-weighted imaging lesion expansion between 2 and 24 h after endovascular thrombectomy in acute ischemic stroke
Purpose Diffusion-weighted imaging (DWI) lesion expansion after endovascular thrombectomy (EVT) is not well characterized. We used serial diffusion-weighted magnetic resonance imaging (MRI) to measure lesion expansion between 2 and 24 h after EVT. Methods In this single-center observational analysis of patients with acute ischemic stroke due to large vessel occlusion, DWI was performed post-EVT (< 2 h after closure) and 24-h later. DWI lesion expansion was evaluated using multivariate generalized linear mixed modeling with various clinical moderators. Results We included 151 patients, of which 133 (88%) had DWI lesion expansion, defined as a positive change in lesion volume between 2 and 24 h. In an unadjusted analysis, median baseline DWI lesion volume immediately post-EVT was 15.0 mL (IQR: 6.6–36.8) and median DWI lesion volume 24 h post-EVT was 20.8 mL (IQR: 9.4–66.6), representing a median change of 6.1 mL (IQR: 1.5–17.7), or a 39% increase. There were no significant associations among univariable models of lesion expansion. Adjusted models of DWI lesion expansion demonstrated that relative lesion expansion (defined as final/initial DWI lesion volume) was consistent across eTICI scores (0–2a, 0.52%; 2b, 0.49%; 2c–3, 0.42%, p = 0.69). For every 1 mL increase in lesion volume, there was 2% odds of an increase in 90-day mRS (OR: 1.021, 95%CI [1.009, 1.034], p < 0.001). Conclusion We observed substantial lesion expansion post-EVT whereby relative lesion expansion was consistent across eTICI categories, and greater absolute lesion expansion was associated with worse clinical outcome. Our findings suggest that alternate endpoints for cerebroprotectant trials may be feasible.
- 26 January 2024
- Published by Springer Nature in Neuroradiology
- Vol. 66 (4) , 621-629
Modeling diffusion-weighted imaging lesion expansion between 2 and 24 h after endovascular thrombectomy in acute ischemic stroke
Purpose Diffusion-weighted imaging (DWI) lesion expansion after endovascular thrombectomy (EVT) is not well characterized. We used serial diffusion-weighted magnetic resonance imaging (MRI) to measure lesion expansion between 2 and 24 h after EVT. Methods In this single-center observational analysis of patients with acute ischemic stroke due to large vessel occlusion, DWI was performed post-EVT (< 2 h after closure) and 24-h later. DWI lesion expansion was evaluated using multivariate generalized linear mixed modeling with various clinical moderators. Results We included 151 patients, of which 133 (88%) had DWI lesion expansion, defined as a positive change in lesion volume between 2 and 24 h. In an unadjusted analysis, median baseline DWI lesion volume immediately post-EVT was 15.0 mL (IQR: 6.6–36.8) and median DWI lesion volume 24 h post-EVT was 20.8 mL (IQR: 9.4–66.6), representing a median change of 6.1 mL (IQR: 1.5–17.7), or a 39% increase. There were no significant associations among univariable models of lesion expansion. Adjusted models of DWI lesion expansion demonstrated that relative lesion expansion (defined as final/initial DWI lesion volume) was consistent across eTICI scores (0–2a, 0.52%; 2b, 0.49%; 2c–3, 0.42%, p = 0.69). For every 1 mL increase in lesion volume, there was 2% odds of an increase in 90-day mRS (OR: 1.021, 95%CI [1.009, 1.034], p < 0.001). Conclusion We observed substantial lesion expansion post-EVT whereby relative lesion expansion was consistent across eTICI categories, and greater absolute lesion expansion was associated with worse clinical outcome. Our findings suggest that alternate endpoints for cerebroprotectant trials may be feasible.